Harland SJ - Search Results

1

Clinical features of patients who present with metastatic prostate carcinoma and serum prostate-specific antigen (PSA) levels < 10 ng/mL: the "PSA negative" patients.

Birtle AJ, Freeman A, Masters JR, Payne HA, Harland SJ; BAUS Section of Oncology Cancer Registry. Birtle AJ, et al. Among authors: harland sj. Cancer. 2003 Dec 1;98(11):2362-7. doi: 10.1002/cncr.11821. Cancer. 2003. PMID: 14635070 Free article.

2

Tumour markers for managing men who present with metastatic prostate cancer and serum prostate-specific antigen levels of <10 ng/mL.

Birtle AJ, Freeman A, Masters JR, Payne HA, Harland SJ; BAUS Section of Oncology Cancer Registry. Birtle AJ, et al. Among authors: harland sj. BJU Int. 2005 Aug;96(3):303-7. doi: 10.1111/j.1464-410X.2005.05619.x. BJU Int. 2005. PMID: 16042718

3

Epirubicin carboplatin and 5-fluorouracil (ECarboF) chemotherapy in metastatic hormone refractory prostate cancer.

Birtle AJ, Newby JC, Harland SJ. Birtle AJ, et al. Among authors: harland sj. Br J Cancer. 2004 Oct 18;91(8):1472-6. doi: 10.1038/sj.bjc.6602177. Br J Cancer. 2004. PMID: 15381936 Free PMC article.

4

Transdermal oestrogen therapy as a second-line hormonal intervention in prostate cancer: a bad experience.

Kandola S, Anyamene N, Payne H, Harland S. Kandola S, et al. BJU Int. 2007 Jan;99(1):53-5. doi: 10.1111/j.1464-410X.2007.06543.x. BJU Int. 2007. PMID: 17227492

5

Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer.

Brown RS, Edwards J, Dogan A, Payne H, Harland SJ, Bartlett JM, Masters JR. Brown RS, et al. Among authors: harland sj. J Pathol. 2002 Oct;198(2):237-44. doi: 10.1002/path.1206. J Pathol. 2002. PMID: 12237884

6

The comparative values of bone marrow aspirate and trephine for obtaining bone scan-targeted metastases from hormone-refractory prostate cancer.

Brown RS, Dogan A, Ell PJ, Payne HA, Masters JR, Harland SJ. Brown RS, et al. Among authors: harland sj. Prostate Cancer Prostatic Dis. 2002;5(2):144-51. doi: 10.1038/sj.pcan.4500581. Prostate Cancer Prostatic Dis. 2002. PMID: 12497005 Clinical Trial.

7

Neuroendocrine differentiation in prostate cancer: is it detectable and treatable?

Birtle AJ, Freeman A, Payne HA, Masters JR, Harland SJ. Birtle AJ, et al. Among authors: harland sj. BJU Int. 2003 Sep;92(4):490. doi: 10.1046/j.1464-410x.2003.t01-1-04376.x. BJU Int. 2003. PMID: 12930449 No abstract available.

8

ThioTEPA pharmacokinetics during intravesical chemotherapy: the influence of dose and volume of instillate on systemic uptake and dose rate to the tumour.

Masters JR, McDermott BJ, Harland S, Bibby MC, Loadman PM. Masters JR, et al. Cancer Chemother Pharmacol. 1996;38(1):59-64. doi: 10.1007/s002800050448. Cancer Chemother Pharmacol. 1996. PMID: 8603453 Clinical Trial.

9

Paraneoplastic Cushing's syndrome in prostate cancer: a difficult management problem.

Nimalasena S, Freeman A, Harland S. Nimalasena S, et al. BJU Int. 2008 Feb;101(4):424-7. doi: 10.1111/j.1464-410X.2007.07294.x. Epub 2007 Dec 7. BJU Int. 2008. PMID: 18070179 Review.

10

A validated prognostic index predicting response to dexamethasone and diethylstilbestrol in castrate-resistant prostate cancer.

Shamash J, Stebbing J, Sweeney C, Sonpavde G, Harland S, Dawkins G, Brock C, Abelman W, Wilson P, Sanitt A, Oliver T, Powles T. Shamash J, et al. Cancer. 2010 Aug 1;116(15):3595-602. doi: 10.1002/cncr.25194. Cancer. 2010. PMID: 20564115 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

104 results

Search Page

Filters